We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NASDAQ:AZN | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.535 | -0.70% | 75.815 | 75.81 | 75.82 | 75.93 | 75.545 | 75.84 | 2,873,250 | 18:32:18 |
From May 2019 to May 2024
--The European Medicines Agency probably won't be able to approve AstraZeneca PLC and the University of Oxford's Covid-19 vaccine in January, says Noel Wathion, the watchdog's deputy executive director, in an interview with Belgian newspaper Het Nieuwsblad.
--The data submitted to the EMA by the vaccine's developers isn't even enough to grant it a conditional marketing license, Wathion tells Het Nieuwsblad.
Full story (in Dutch): https://bit.ly/34QhY06
Write to Barcelona editors at barcelonaeditors@dowjones.com
(END) Dow Jones Newswires
December 29, 2020 09:19 ET (14:19 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
